Mr. Market's non-response notwithstanding, Johnson & Johnson (JNJ +2.08%) turned in a great second quarter. But with any company as big as J&J, not every investor question can be answered, and sometimes the leftover question marks are pretty big.
Below are three crucial questions Motley Fool health care analysts Michael Douglass and David Williamson think J&J still needs to answer.
